Annovis Bio Q3 net loss per share narrows even as R&D spending rises
ANVS•Annovis Bio reported a Q3 loss per share of $0.22, while research and development expenses more than doubled year over year. The company raised $21 million in a public offering and expects the financing to fund operations through its March 2027 DUET-AD data readout.
1. Quarterly results
Annovis Bio’s Q3 net loss per share narrowed from a year earlier to $0.22, even as research and development expenses more than doubled year over year as clinical trials advanced.
2. Funding and trials
The company raised $21 million in gross proceeds through a public offering, which it expects to fund operations through the six-month DUET-AD data readout. Annovis expects topline results from the six-month analysis in March 2027 and projects OLE-PD study enrollment will close by January 29, 2027.
